Chaseton Nielsen, DO
Family Medicine · Sanford, NCNPI 1760985600
Payments from drug & device makers
Across 252 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$363
- Lilly USA, LLC$255
- Boehringer Ingelheim$189
- GSK$175
- Daiichi Sankyo Inc.$143
- plus $1K from 33 others
What the payments were for
- Food & beverage$4,388100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 98 | $1,774 |
| AbbVie | 23 | $363 |
| Lilly USA, LLC | 20 | $255 |
| Boehringer Ingelheim | 9 | $189 |
| GSK | 9 | $175 |
| Daiichi Sankyo Inc. | 7 | $143 |
| Bayer | 9 | $143 |
| Amgen(2 entities) | 10 | $129 |
| Merck | 7 | $122 |
| Novartis | 7 | $121 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
| Exact Sciences | 5 | $91 |
| Sanofi-aventis U.S. LLC | 4 | $87 |
| Pfizer | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| Grifols USA, LLC | 2 | $45 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $44 |
| Shield Therapeutics Inc | 2 | $39 |
| AstraZeneca | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Abbott | 1 | $31 |
| Intrabio Inc | 1 | $26 |
| Boston Scientific | 1 | $25 |
| Corcept Therapeutics | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Kaleo, Inc. | 1 | $14 |
| Tonix Medicines, Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $13 |
| IBSA Pharma Inc. | 1 | $13 |
| Agile Therapeutics, Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$125
How this compares
$4,388 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $149,308 |
| JardianceEmpagliflozin | 180 | $127,202 |
| MounjaroTirzepatide | 64 | $75,992 |
| RybelsusSemaglutide | 65 | $66,294 |
| EliquisApixaban | 67 | $60,140 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $38,158 |
| FarxigaDapagliflozin Propanediol | 39 | $31,053 |
| LinzessLinaclotide | 25 | $18,293 |
| XareltoRivaroxaban | 26 | $17,295 |
| LatudaLurasidone Hcl | 11 | $14,831 |
| JanuviaSitagliptin Phosphate | 13 | $10,728 |
| Repatha SureclickEvolocumab | 14 | $7,480 |
| Atorvastatin Calcium | 555 | $5,736 |
| BelsomraSuvorexant | 12 | $5,455 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $4,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,774 | $215,602174 claims |
| Boehringer IngelheimJardiance | $189 | $127,202180 claims |
| Lilly USA, LLCMounjaro | $255 | $75,99264 claims |
| PfizerEliquis, Prempro | $76 | $64,60778 claims |
| GSKTrelegy Ellipta | $175 | $38,15852 claims |
| AstraZenecaFarxiga, Symbicort | $37 | $34,64053 claims |
| AbbVieLinzess, Synthroid | $363 | $20,98253 claims |
| MerckJanuvia, Belsomra | $122 | $16,18325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Sanford
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.